secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuphoria Therapeutics Inc. (NEUP)
CIK:        0001191070
Form:       8-K
Filed at:   2026-07-23T22:37:29+00:00
Accession:  0001213900-26-081052
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 5.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuphoria Therapeutics to be acquired by Scancell Holdings in all-stock merger with CVRs
--------------------------------------------------------------------------------

- Neuphoria shareholders to receive Parent ADSs and contingent value rights; expected to own ~11.1% of combined company.
- Scancell shareholders to own ~64.9%; PIPE investors to own ~17.3% with $38.6M gross proceeds at $0.1205/ADS.
- Closing conditions include stockholder approvals, Nasdaq listing of Parent ADSs, and at least $75M in PIPE proceeds.
- CVRs entitle holders to 100% of net proceeds from Merck collaboration, Pfizer/KAT6 license, and R&D tax credit over 15 years.
- UK Placing of ~$12M and Retail Offer up to $3M also announced; not conditional on merger completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1191070/000121390026081052/0001213900-26-081052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1191070/000121390026081052/ea0298914-8k_neuphoria.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-081052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer